Back to search

Article

Antibody Responses to SARS-CoV-2 Infection in Cancer Patients

2021-01-08

Abstract excerpt

Background: Literature is sparse about the prevalence and durability of immune response to infection with Severe Acute Respiratory Syndrome Coronavirus 2( SARS-CoV-2 ) / Coronavirus Disease (COVID-19) in cancer patients. <br><br>Method: We retrospectively analyzed antibody levels and seroconversion rates in serum samples from 135 cancer patients recovered from SARS-CoV-2 infection. Chemiluminescent Immunoassay...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0c40cc1c-8103-5ec6-999c-d322358ad4e2
DOI
10.2139/ssrn.3762626
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antibody Responses to SARS-CoV-2 Infection in Cancer PatientsDOI 10.2139/ssrn.3762626
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
Durable tracking anti-SARS-CoV-2 antibodies of cancer patients recovered from COVID-19Semantic proximity
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer patients: Short ReviewSemantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsSemantic proximity
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity
SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in PortugalSemantic proximity
Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study)Semantic proximity
SARS-CoV-2 antibody responses in patients with aggressive haematological malignanciesSemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.